Hyperpolarized Imaging for Meningioma
This study is looking into a new way to get detailed images of meningioma (a type of brain tumor) using a special MRI technique. It involves giving you a substance called hyperpolarized carbon C 13 pyruvate intravenously (into your vein) before an MRI scan. The main goal is to see if this imaging method can successfully be used in people with meningioma. To join, you need to be at least 18 years old and have a known or suspected meningioma that shows up on an MRI. The study aims to enroll 50 participants, but the current recruitment status is unclear.
- Study design
- This is a pilot/Phase I interventional study involving 50 participants with meningioma.
- What's involved
- You will receive a single imaging procedure with hyperpolarized carbon C 13 pyruvate and an MRI. You will then be followed for 30 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 30 days after the study or until withdrawal or death.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Charlie Wang, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of participants who complete 13C pyruvate MR imaging.Day of MR imaging (1 day)
All participants who are enrolled in the study and receive any amount of hyperpolarized 13C pyruvate will be included in the primary outcome analysis. The proportion of participants who complete hyperpolarized 13C pyruvate MR imaging will be reported. If the proportion is greater than 0.7, hyperpolarized 13C MR imaging will be determined to be feasible.